Beigene Initiated Global Phase II Clinical Trial for PD-1 Antibody

BeiGene announced the initiation of a multi-center Phase II clinical trial of tislelizumab, an anti-PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma (HCC or liver cancer). [Gabbie: Technically, the "trial" can't "plan" -- only the company or people can plan] The company plans to enroll 225 patients in the Phase II trial at 75 cancer centers in Greater China (including Taiwan ), US and EU. Celgene, which signed a $1.4 billion deal for ex-Asia rights to the PD-1 candidate last year, will co-develop the drug with BeiGene in ex-Asia markets. BeiGene is now testing tislelizumab in three global Phase III trials. More details.... Share this with colleagues: // //   Stock Symble: (NASDAQ: BGNE)